CARFILZOMIB AND DEXAMETHASONE VS SUBCUTANEOUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SECONDARY ANALYSIS FROM THE PHASE 3 STUDY ENDEAVOR (NCT01568866)

MLA

Goldschmidt, H., et al. Carfilzomib and Dexamethasone Vs Subcutaneous Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Secondary Analysis from the Phase 3 Study Endeavor (Nct01568866). EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..4cbe3280ca904167a3765814cf46c77b&authtype=sso&custid=ns315887. Accessed 10 Nov. 2024.

APA

Goldschmidt, H., Moreau, P., Palumbo, A., Joshua, U., Pour, L., Roman Hajek, Facon, T., Ludwig, H., Niesvizky, R., Oriol, A., Rosinol, L., Straub, J., Suvorov, A., Araujo, C., Rimashevskaya, E., Pika, T., Gaidano, G., Weisel, K., Goronova-Marinova, V., … Dimopoulos, M. (n.d.). Carfilzomib and Dexamethasone Vs Subcutaneous Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Secondary Analysis from the Phase 3 Study Endeavor (Nct01568866).

Chicago

Goldschmidt, H., P. Moreau, A. Palumbo, U. Joshua, L. Pour, Roman Hajek, T. Facon, et al. 2024. “Carfilzomib and Dexamethasone Vs Subcutaneous Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Secondary Analysis from the Phase 3 Study Endeavor (Nct01568866).” Accessed November 10. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..4cbe3280ca904167a3765814cf46c77b&authtype=sso&custid=ns315887.